JP2013541521A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013541521A5 JP2013541521A5 JP2013528649A JP2013528649A JP2013541521A5 JP 2013541521 A5 JP2013541521 A5 JP 2013541521A5 JP 2013528649 A JP2013528649 A JP 2013528649A JP 2013528649 A JP2013528649 A JP 2013528649A JP 2013541521 A5 JP2013541521 A5 JP 2013541521A5
- Authority
- JP
- Japan
- Prior art keywords
- substitution
- fviii variant
- fviii
- amino acid
- charged amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100026735 Coagulation factor VIII Human genes 0.000 claims 23
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims 23
- 238000006467 substitution reaction Methods 0.000 claims 21
- 125000000539 amino acid group Chemical group 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 208000031220 Hemophilia Diseases 0.000 claims 1
- 208000009292 Hemophilia A Diseases 0.000 claims 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical group OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims 1
- 102100021923 Prolow-density lipoprotein receptor-related protein 1 Human genes 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 1
- 230000004700 cellular uptake Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Chemical group OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 1
- 230000005847 immunogenicity Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10176731 | 2010-09-15 | ||
| EP10176731.7 | 2010-09-15 | ||
| US38473110P | 2010-09-21 | 2010-09-21 | |
| US61/384,731 | 2010-09-21 | ||
| EP11173768.0 | 2011-07-13 | ||
| EP11173768 | 2011-07-13 | ||
| US201161507666P | 2011-07-14 | 2011-07-14 | |
| US61/507,666 | 2011-07-14 | ||
| PCT/EP2011/065913 WO2012035050A2 (en) | 2010-09-15 | 2011-09-14 | Factor viii variants having a decreased cellular uptake |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016134866A Division JP6336522B2 (ja) | 2010-09-15 | 2016-07-07 | 細胞取込みが低下した第ｖｉｉｉ因子変異体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013541521A JP2013541521A (ja) | 2013-11-14 |
| JP2013541521A5 true JP2013541521A5 (enExample) | 2014-11-06 |
| JP6042335B2 JP6042335B2 (ja) | 2016-12-14 |
Family
ID=45832010
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013528649A Expired - Fee Related JP6042335B2 (ja) | 2010-09-15 | 2011-09-14 | 細胞取込みが低下した第ｖｉｉｉ因子変異体 |
| JP2016134866A Expired - Fee Related JP6336522B2 (ja) | 2010-09-15 | 2016-07-07 | 細胞取込みが低下した第ｖｉｉｉ因子変異体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016134866A Expired - Fee Related JP6336522B2 (ja) | 2010-09-15 | 2016-07-07 | 細胞取込みが低下した第ｖｉｉｉ因子変異体 |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US9321827B2 (enExample) |
| EP (2) | EP3466968A1 (enExample) |
| JP (2) | JP6042335B2 (enExample) |
| CN (2) | CN103209992A (enExample) |
| AU (1) | AU2011303916A1 (enExample) |
| PL (1) | PL2616486T3 (enExample) |
| WO (1) | WO2012035050A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2742949A1 (en) * | 2009-11-13 | 2014-06-18 | Puget Sound Blood Center | Factor VIII B cell epitope variants having reduced immunogenicity |
| WO2013160005A1 (en) | 2012-04-24 | 2013-10-31 | Novo Nordisk A/S | Pharmaceutical composition suitable for treatment of haemophilia |
| JP2015515482A (ja) | 2012-04-24 | 2015-05-28 | ノヴォ ノルディスク アー／エス | 血友病の治療に適する化合物 |
| CN104661685A (zh) | 2012-10-15 | 2015-05-27 | 诺和诺德保健Ag（股份有限公司） | 因子vii缀合物 |
| BR112015014753B8 (pt) | 2012-12-20 | 2020-03-03 | Basf Agro Bv | composições, uso de uma composição, método para o combate de fungos fitopatogênicos e uso dos componentes |
| BR122019013926B1 (pt) | 2013-01-09 | 2019-10-29 | Basf Agro Bv | processo para preparar um composto de triazol de fórmula i |
| UA118265C2 (uk) | 2013-07-08 | 2018-12-26 | Басф Агро Б.В. | Композиції, що містять триазольну сполуку і біопестицид |
| BR112016008039A2 (pt) | 2013-10-15 | 2017-10-17 | Novo Nordisk Healthcare Ag | polipeptídeos do fator vii da coagulação |
| WO2015132724A1 (en) | 2014-03-05 | 2015-09-11 | Pfizer Inc. | Improved muteins of clotting factor viii |
| UA119672C2 (uk) | 2014-06-25 | 2019-07-25 | Басф Агро Б.В. | Пестицидні композиції |
| JP7261739B2 (ja) * | 2017-04-27 | 2023-04-20 | 中外製薬株式会社 | 薬物動態が改善された血液凝固第ｉｘ因子 |
| AU2019366942B2 (en) * | 2018-10-23 | 2025-10-30 | The Children's Hospital Of Philadelphia | Compositions and methods for modulating factor VIII function |
| MY206180A (en) | 2019-04-17 | 2024-12-03 | Novo Nordisk As | Bispecific antibodies |
| EP4147056A1 (en) * | 2020-05-08 | 2023-03-15 | UCB Biopharma SRL | Arrays and methods for identifying binding sites on a protein |
| CN113248594B (zh) * | 2021-04-26 | 2022-08-30 | 北京美康基免生物科技有限公司 | 一种重组凝血因子viii及其应用 |
| WO2025164792A1 (ja) * | 2024-02-02 | 2025-08-07 | 学校法人自治医科大学 | 高比活性／高分泌発現型の第ｖｉｉｉ因子改変体、高発現型の第ｖｉｉｉ因子コード核酸及びそれらの用途 |
| WO2025168826A1 (en) | 2024-02-08 | 2025-08-14 | Hemab Aps | Methods of treating coagulopathy |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2645588A (en) | 1987-12-04 | 1989-06-15 | Scripps Clinic And Research Foundation | The von willebrand factor binding domain of factor viii |
| SE465222C5 (sv) * | 1989-12-15 | 1998-02-10 | Pharmacia & Upjohn Ab | Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning |
| AU6029594A (en) * | 1993-01-15 | 1994-08-15 | Enzon, Inc. | Factor viii - polymeric conjugates |
| SE504074C2 (sv) * | 1993-07-05 | 1996-11-04 | Pharmacia Ab | Proteinberedning för subkutan, intramuskulär eller intradermal administrering |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| CN100335503C (zh) | 1998-04-28 | 2007-09-05 | 应用研究系统Ars股份公司 | 多元醇干扰素β偶联物 |
| US6759216B1 (en) | 1998-11-06 | 2004-07-06 | Emory University | Glycosylated, low antigenicity low immunogenicity factor VIII |
| AU775529B2 (en) | 1998-11-10 | 2004-08-05 | Stichting Sanquin Bloedvoorziening | A factor VIII-polypeptide with factor VIII:C-activity |
| ES2411007T3 (es) * | 2001-10-10 | 2013-07-04 | Novo Nordisk A/S | Remodelación y glicoconjugación de péptidos |
| JP4758608B2 (ja) * | 2001-11-07 | 2011-08-31 | ネクター セラピューティックス | 分枝ポリマーおよびそれらの結合体 |
| US20040249134A1 (en) * | 2001-11-30 | 2004-12-09 | Lollar John S. | Factor viii c2 domain variants |
| AU2003227687B2 (en) | 2002-04-29 | 2009-10-15 | Stichting Sanquin Bloedvoorziening | Antagonists of factor VIII interaction with low-density lipoprotein receptor-related protein |
| US7645860B2 (en) | 2006-03-31 | 2010-01-12 | Baxter Healthcare S.A. | Factor VIII polymer conjugates |
| US20100056428A1 (en) | 2006-09-01 | 2010-03-04 | Novo Nordisk Health Care Ag | Modified proteins |
| WO2008151258A2 (en) * | 2007-06-04 | 2008-12-11 | Neose Technologies, Inc. | O-linked glycosylation using n-acetylglucosaminyl transferases |
| RU2573587C2 (ru) | 2008-02-27 | 2016-01-20 | Ново Нордиск А/С | Конъюгированные молекулы фактора viii |
| EP2742949A1 (en) | 2009-11-13 | 2014-06-18 | Puget Sound Blood Center | Factor VIII B cell epitope variants having reduced immunogenicity |
-
2011
- 2011-09-14 CN CN2011800549583A patent/CN103209992A/zh active Pending
- 2011-09-14 EP EP18195448.8A patent/EP3466968A1/en not_active Withdrawn
- 2011-09-14 CN CN201510070728.6A patent/CN104788557A/zh active Pending
- 2011-09-14 JP JP2013528649A patent/JP6042335B2/ja not_active Expired - Fee Related
- 2011-09-14 AU AU2011303916A patent/AU2011303916A1/en not_active Abandoned
- 2011-09-14 PL PL11769805T patent/PL2616486T3/pl unknown
- 2011-09-14 US US13/822,942 patent/US9321827B2/en not_active Expired - Fee Related
- 2011-09-14 WO PCT/EP2011/065913 patent/WO2012035050A2/en not_active Ceased
- 2011-09-14 EP EP11769805.0A patent/EP2616486B1/en not_active Not-in-force
-
2015
- 2015-09-23 US US14/862,934 patent/US20160002314A1/en not_active Abandoned
-
2016
- 2016-07-07 JP JP2016134866A patent/JP6336522B2/ja not_active Expired - Fee Related
- 2016-11-18 US US15/355,475 patent/US10047142B2/en active Active
-
2018
- 2018-07-06 US US16/028,603 patent/US10906960B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013541521A5 (enExample) | ||
| CA2818990C (en) | Designed repeat proteins binding to serum albumin | |
| SG10201900695PA (en) | Functionalized benzamide derivatives as antiviral agents against hbv infection | |
| PH12014501924A1 (en) | Xten conjugate compositions and methods of making same | |
| CL2013002474A1 (es) | Compuestos derivados de piperidina puenteada (3-aza-biciclo[3.2.1]oct-8-il), moduladores de b-amiloide; procedimiento de preparación; composición farmacéutica; y uso en el tratamiento de enfermedades tales como alzheimer, síndrome de down, entre otras. | |
| WO2017044894A3 (en) | Cartilage-homing peptides | |
| JP2013542247A5 (enExample) | ||
| CL2008000690A1 (es) | Compuestos derivados del acido indol-3-propionico; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hiperlipidemia, hipertension; entre otras. | |
| IL214942A (en) | N, n– Dimethyl-5– (2-methyl-6 - ((5-methylpyrazine-2-yl) carbamole) Benzoporen-4-Iloxy) Pyrimidine-2-carboxamide and the salts common in its pharmacies, pharmaceuticals containing them and their uses in the preparation of drugs | |
| HRP20251088T1 (hr) | Upotreba dugodjelujućih peptida glp‑1 | |
| WO2014150600A3 (en) | Modified toxins | |
| MX366906B (es) | Purificacion de iduronato-2-sulfatasa. | |
| BR112013026363A2 (pt) | nanossuspensões de fármaco criodessecadas | |
| BR112012016853A2 (pt) | "composições farmacêuticas para administração oral de peptídeos de insulina". | |
| PH12014500635B1 (en) | Therapeutic peptides | |
| EP2753348A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CANCER WITH AN INTERFERON ALPHA CONJUGATE | |
| PH12015501982A1 (en) | Pharmaceutical compositions comprising everolimus | |
| EA201590491A1 (ru) | Иммуногенная композиция | |
| EP3309555A3 (en) | Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation | |
| AR087227A1 (es) | CONJUGADO DE INTERFERON a CON POLIETILENGLICOL | |
| WO2012177660A3 (en) | Leukotoxin e/d as a new anti-inflammatory agent and microbicide | |
| JP2017513944A5 (enExample) | ||
| JP2013542196A5 (enExample) | ||
| HRP20170794T1 (hr) | Izvedeni peptidi faktora viii za upotrebu u liječenju hemofilije a | |
| CL2008000726A1 (es) | Compuestos derivados de heterociclos nitrogenados condensados; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como esquizofrenia, alzheimer, entre otras. |